Best Genomics Companies in Wisconsin, United States
The 45 best Genomics companies in Wisconsin, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Scarab Genomics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Wisconsin
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Scarab Genomics Developer of bioengineered E.coli strains for a range of applications | $26M | 23 mo ago | 16 | — | — | 148 patents Synthetic genome engineering and optimized recombinant protein production in engineered microbes | — |
| 2 | DNASTAR Provider of software for genomics, structural biology, and clinical research | $22M | 15 mo ago | 41 41 → 26 (-37%) | — | WordPressMySQLRedis+44 | 7 patents Computational genomics and protein structure modeling software for sequence assembly and prediction | 3 launchs |
| 3 | TAI Diagnostics Provider of diagnostic solutions for transplant patients | $21M | 97 mo ago | 30 | — | — | — | — |
| 4 | EraGen Biosciences Molecular Reagent Products and molecular diagnostic products for early detection and monitoring of cancer… | $21M | 215 mo ago | 50 | — | — | 49 patents Synthetic non‑standard nucleic acids and related detection/assay technologies. | — |
| 5 | BioSentinel Innovative BoNT detection and potency testing solutions for biodefense and pharmaceutical applications | $21M | 178 mo ago | 16 | — | — | 14 patents FRET-based protease assay kits for detecting botulinum neurotoxin activity | — |
| 6 | GenoPalate Provider of personalized diet plans based on the genetic disposition 48Tech top 27%Talent top 28%Growth top 35%Funding top 40% All 9 signals ▾Techtop 27% Talenttop 28% Growthtop 35% Fundingtop 40% Productbottom 48% Customersbottom 40% Globalbottom 29% Marketbottom 24% Newsbottom 18% Tech: 67 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 48/100 | $12M | 6 mo ago | 15 | — | Cart FunctionalityShopifySentry+57 | — | 1 partnership |
| 7 | NovaScan Developer of diagnostic platform technology for cancer detection 32Innovation top 26%Patents top 26%Moat top 32%Funding top 36% All 8 signals ▾Innovationtop 26% Patentstop 26% Moattop 32% Fundingtop 36% Talentbottom 49% Globalbottom 40% Marketbottom 24% Techbottom 24% Innovation: 57 patents (top 28% of patent-holders) · 40 filings since 2022 vs 17 in 2017-21 Patents: 57 patents matched (strict assignee match) · 40 filings since 2022 vs 17 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $8M | 3 mo ago | 16 | Craig Davis President and CEO | WordPressMySQLPHP+11 | 57 patents Intraoperative cancer detection via impedance-based tissue characterization and device control | — |
| 8 | Gregor Diagnostics Provider of non-invasive screening test for prostate cancer | $7M | 10 mo ago | 12 | Steven Weinstein CEO | — | — | — |
| 9 | Mirus Bio Developer of transfection reagents and electroporation products | $7M | 215 mo ago | 33 33 → 63 (+91%) | — | WordPressSalesforceSalesforce Service Cloud+30 | — | — |
| 10 | PhylloTech Biotechnology company providing protein products for research use, including cytokines and other products | $6M | 14 mo ago | 2 | Colin Shepherd Co-Founder & COO | — | — | — |
| 11 | Lucigen Genomics solutions provider: reagents, instruments, and services for life science research | $5M | 137 mo ago | 65 | — | — | 45 patents Engineered DNA polymerases and nucleic‑acid diagnostic/sample‑collection technologies | 1 launch |
| 12 | Pointcare Genomics Liquid biopsy based assays | $4M | 140 mo ago | — | Tonny Johnson CEO | — | — | — |
| 13 | Intuitive Bio Immunoassay products and services for biomedical research, enhancing lab effectiveness | $4M | 82 mo ago | 9 | — | — | — | — |
| 14 | Prodesse Prodesse develops molecular diagnostic reagents for infectious disease applications. | $4M | 253 mo ago | — | Stephen MacMillan CEO & Chairman | — | — | — |
| 15 | Proteovista Provider of bioinformatics services and DNA-binding assay development | $3M | 41 mo ago | 5 | Mary Ozers Co-Founder | — | 4 patents High-throughput SNP genotyping arrays for genetic variation analysis | — |
| 16 | Capio Biosciences Provider of a platform for isolation of circulating tumor cells | $3M | 115 mo ago | 5 | — | — | — | — |
| 17 | Thermagenix PCR additives enhancing polymerase specificity and fidelity for superior amplicons | $2M | 84 mo ago | 6 | — | — | — | — |
| 18 | Geno.Me Online platform offering data mining tools for gene analysis | $400K | 15 mo ago | 6 | Britt Gottschalk Founder & CEO | — | 200 patents Medical nitric oxide generation, storage, delivery systems, and related diagnostic methods | — |
| 19 | LifeGen Technologies Genomics company discovering the genetic basis of aging to increase healthy lifespan | $248K | 191 mo ago | 26 | Tomas Prolla Co-Founder | — | 6 patents Identification of tissue-specific aging biomarkers for longevity and healthspan assessment. | — |
| 20 | Pattern Genomics Specializes in application of large-scale bioinformatics sequence analysis for molecular assay design | $150K | 161 mo ago | 2 | — | — | — | — |
| 21 | Terra Bioforge Provider of a synthetic biology platform for discovering microbial products | $100K | 38 mo ago | 9 | Mark Liles Co-Founder | — | — | — |
| 22 | Promega Provider of genomics, protein analysis and expression, drug discovery, and genetic identification products | — | 139 mo ago | 659 | — | — | 1,700 patents Bioluminescent reporter enzymes, assay reagents, and delivery polymers for molecular biology | — |
Top 12 Genomics companies in Wisconsin
#1
Series B · Milwaukee, Wisconsin · founded 2001 · 16 employees$8.1Mraised▾
Developer of diagnostic platform technology for cancer detection. The proprietary impedance-based platform technology for the detection of cancers. The company has developed a single impedance parameter that differs markedly between healthy and cancer tissue, called the Cole Relaxation Frequency.
- Nov 2021Series B$8M
- Sep 2020Seed$100K
- Jul 2017Seed$50K
- Jan 2011Grant (prize money)$1.1M
#2
Series A · Milwaukee, Wisconsin · founded 2016 · 15 employees$12.4Mraised▾
Provider of personalized diet plans based on the genetic disposition. The platform provides a DNA test kit for sample collection and analyses the sample using the proprietary algorithm to provide a report. The company provides insights into diet and food recommendations based on the results. A customized tool kit with nutritional information and advice is provided for consumers.
- Feb 2026Series A$250K
- Oct 2024Series A$3M
- Oct 2022Series A$5.6M
- Dec 2020Series A$4M
#3
Series A · Madison, Wisconsin · founded 2016 · 12 employees$7.2Mraised▾
Provider of non-invasive screening test for prostate cancer. The company's proprietary assay analyzes seminal fluid for the presence of eight cancer-associated biomarkers that may be missed in blood or urine-based tests. The assay will stratify patients into no cancer, indolent cancer, and aggressive cancer levels. Patients can receive an at-home sample collection kit and send it to the company for analysis.
- Oct 2025Series A$242K
- Nov 2023Conventional Debt$6M
- Mar 2023Series A$7.4M
- Oct 2019Seed$915.7K
#4
Funding Raised · Madison, Wisconsin · founded 1984 · 41 employees$22Mraised▾
Provider of software for genomics, structural biology, and clinical research. The solutions include DNASTAR Lasergene Suite for genomics, structural biology, and molecular biology research, Molecular Biology Suite which can be used for multiple and pairwise sequence alignments, identify genes, assemble contigs of Sanger sequences, create clones, and other services.
- May 2025Grant (prize money)$6M
- Aug 2023Grant (prize money)$1.3M
- May 2020Grant (prize money)$5M
- Apr 2020Grant (prize money)$1.5M
#5
Funding Raised · Madison, Wisconsin · founded 2009 · 2 employees$6.1Mraised▾
Biotechnology company providing protein products for research use, including cytokines and other products. It is a biotechnology company that specializes in developing and manufacturing endotoxin-free protein products for research use. The company offers a growing catalog of RUO cytokines and other products for sale, catering to the needs of research institutions and organizations. Its products are used in various applications, including biopesticides, plant-based pharmaceuticals, and medical research.
- May 2025Grant (prize money)$1M
- Jun 2020Grant (prize money)$256K
- Feb 2020Grant (prize money)$1.1M
- Sep 2016Grant (prize money)$916K
#6
Funding Raised · Madison, Wisconsin · founded 2002 · 16 employees$25.9Mraised▾
Developer of bioengineered E.coli strains for a range of applications. The company has developed clean genome E. coli, a unique, patented set of bacterial hosts for reliable, high-efficiency production of protein and nucleic acid biopharmaceuticals. The product line includes vaccine carrier proteins, vectors, and diagnosis kits.
- Sep 2024Grant (prize money)$842.2K
- Jul 2020Grant (prize money)$2.9M
- Jan 2019Grant (prize money)$1.8M
- Dec 2016Grant (prize money)$1.7M
#7
Seed · Milwaukee, Wisconsin · founded 2020 · 6 employees$400Kraised▾
Online platform offering data mining tools for gene analysis. The platform connects electronic health record data with genomic information from other services for furthering medical research. The individuals who have contributed to sharing their data are compensated on monthly basis without compromising the data privacy and anonymity.
- Apr 2025Seed$200K
- Nov 2021Seed$400K
#8
Funding Raised · Madison, Wisconsin · founded 2007 · 16 employees$20.8Mraised▾
Innovative BoNT detection and potency testing solutions for biodefense and pharmaceutical applications. They develop cutting-edge tools and reagents for studying botulinum neurotoxin, setting new standards for speed, sensitivity, and accuracy while reducing costs and animal usage. Their assays detect BoNT rapidly, rivaling the gold standard mouse bioassay. They offer a suite of assays for detection and quantification of BoNT in diverse samples, including food, serum, purified toxin, and drug product samples. They design rapid, sensitive tests for BoNTs, addressing the needs of biodefense and pharmaceutical companies. Their technology supports research and development programs, fostering collaborations to develop innovative technologies for the detection, characterization, and quantification of BoNTs. They provide animal-free products and services for BoNT detection and quantification.
- Oct 2011Grant (prize money)$1M
- Jul 2011Grant (prize money)$1.4M
- Jan 2011Grant (prize money)$212.3K
- Jun 2010Grant (prize money)$7.7M
#9
Funding Raised · Madison, Wisconsin · founded 2011 · 5 employees$3.1Mraised▾
Provider of bioinformatics services and DNA-binding assay development. The company's SNAP technology allows the determination of any DNA-binding molecule by utilizing the massively-multiplexed nature of DNA microarrays. Also, it offers bioinformatics consulting across various applications such as arrays, NGS, and ChIP-seq.
- Mar 2023Grant (prize money)$376.8K
- Sep 2019Grant (prize money)$224.5K
- May 2019Grant (prize money)$569.6K
- Aug 2018Grant (prize money)$222.7K
#10
Series A · Milwaukee, Wisconsin · founded 2013 · 30 employees$21.1Mraised▾
Provider of diagnostic solutions for transplant patients. Its flagship product is a non-invasive blood test that can be used to monitor if heart transplant patients are rejecting the new organ by measuring the levels of cell-free DNA originating from the transplanted organ in the patient's blood. Its founding team was previously involved with Ariosa Diagnostics, which was acquired by Roche.
- Jun 2018Series A$12.8M
- Oct 2015Series A$8.3M
#11
Acquired · Madison, Wisconsin · founded 1994 · 50 employees$21Mraised▾
EraGen Biosciences develops, manufactures, and markets molecular reagent products and software for research and clinical testing markets. The company offers molecular diagnostic assays for the early detection and monitoring of cancer, genetic, and infectious diseases, as well as for genetic-based conditions. Its products include molecular diagnostic tests, analyte specific reagents, in vitro diagnostic reagents, and research use only reagents; MultiCode-PLx Analysis Software that allows users to create customized templates for plate and assay layouts; and MultiCode-RTx Analysis Software, which enables users to create templates for quantitative and qualitative analyses. The company serves clinical laboratories and medical researchers. It sells its products through distributors in the United States and Canada. Company was acquired by luminex corp in 2011
- Sep 2008Grant (prize money)$100K
- Jan 2006Series A$12M
#12
Acquired · Madison, Wisconsin · founded 1995 · 33 employees$6.8Mraised▾
Developer of transfection reagents and electroporation products. The company's products include TransIT-VirusTransfection Reagent and Kits, virus production, and transduction products. It also offers delivery systems for molecular and cell biology applications.
- Sep 2008Grant (prize money)$155.1K
- Aug 2007Grant (prize money)$5.4M
- Oct 2004Grant (prize money)$1.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Wisconsin is moving
A read on the academic research around Bioinformatics in Wisconsin — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 182 papers.
- University of Wisconsin–Madison128
- Medical College of Wisconsin33
- University of Wisconsin System9
- University of Wisconsin–River Falls7
- University of Wisconsin Carbone Cancer Center7
- Gene1→9
- Genome2→10
- Proteomics1→5
- Disease9
- Arabidopsis thaliana6
- Arabidopsis6
- Gene6
- Metabolomics5
- DNA methylation3
- Disease3
- Clinical trial2
- Virtual screening2
- Epigenetics2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.